Navidea Stock Gains After FDA Grants End Of Phase 2 Meeting To Discuss Rheumatoid Arthritis Program

by Vandana Singh, Benzinga Editor

July 15, 2021 8:48 AM | 1 min read |

The FDA has granted Navidea Biopharmaceuticals Inc's NAVB request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in Rheumatoid Arthritis and advancement to the Phase 3 trial.
The meeting will take place on September 1 via conference call.
The meeting will be centered on a discussion of results from Phase 2b NAV3-31 study of Tc99m tilmanocept imaging.
The Phase 3 trial will establish the ability of Tc99m tilmanocept imaging to serve as an early predictor of treatment response in RA patients switching to an anti-TNFα therapy.
Price Action: NAVB shares are up 9.92% at $1.99 during the premarket session on the last check Thursday.
Related content: Benzinga's Full FDA Calendar.

Posted In: Biotech Long Ideas News Penny Stocks Health Care FDA Movers Trading Ideas General Briefs rheumatoid arthritis

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.